Investor Presentaiton
ProstACT GLOBAL Phase III study
Pivotal trial
PROSTACT
TARGET
TLX591 + Standard of Care (SoC) vs. SoC alone
Eligible Patients
PSMA avid (defined by TLX591-CDX)
·
mCRPC1
•
Progressed despite prior therapy with NAAD2
For personal use only
TLX591 + Standard of
care therapy
Standard of care therapy
alone
International, multi-centre, Phase III RCT in ~390 patients with PSMA-expressing metastatic prostate cancer
(mCRPC), experiencing disease progression following prior treatment with an anti-androgen drug (NAAD)
•
Primary endpoint: radiographic progression-free survival (rPFS)
Secondary endpoints include: overall survival, quality of life, safety
.
•
2:1 randomisation and enrichment of study population, patient selection with TLX591-CDx
Status: ProstACT GLOBAL has been initiated in Australia and will add EU, US and potentially Chinese sites
over the next six months, subject to satisfying the requisite regulator approvals
1. Metastatic castrate-resistant prostate cancer
2. Novel androgen axis drug
Telix Pharmaceuticals Limited (ASX: TLX)
30
30
TELIX
PHARMACEUTICALSView entire presentation